Quick Facts: Approved Therapeutic Applications

• General Anesthesia: Induces loss of consciousness for surgical and diagnostic procedures.
• Induction Agent: Used to begin anesthesia before administering other general anesthetic agents.
• Anesthetic Supplement: Utilized to support the effects of other anesthetic medications.

---

Ketamin-Actavis (ketamine hydrochloride) is indicated for use in a hospital or other controlled medical setting to achieve general anesthesia. This medication is utilized as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation.

The medication is also applied to induce anesthesia prior to the administration of other general anesthetic agents. Furthermore, it serves as an anesthetic supplement to other agents. Its utility is noted particularly in procedures involving poor-risk patients or when the intramuscular route of administration is preferred for induction.

Ketamine provides pain management during procedures and is associated with the maintenance of certain protective reflexes and cardiovascular function when compared to some other agents.

Eligibility Map: Who can and cannot use Ketamin-Actavis — Official Regulatory Information

The eligibility for Ketamin-Actavis (Ketamine Hydrochloride) is governed by specific restrictions and contraindications detailed in governmental regulatory documents.

Category	Status According to Regulatory Documents
Populations for whom use is allowed	Adult and Pediatric patients for the induction and maintenance of general anesthesia.
Populations for whom use is contraindicated	Patients with known hypersensitivity to ketamine. Patients for whom a significant elevation of blood pressure would constitute a serious hazard, including those with uncontrolled severe hypertension, eclampsia or pre-eclampsia, or a history of stroke or severe myocardial disease.
Age-related eligibility rules	Approved for use in pediatric patients; however, safety has not been fully established in children under three months of age. Caution is required for older adults (geriatric patients).
Condition-specific eligibility rules	Use requires caution and monitoring in patients with elevated intracranial pressure or active psychosis. A dose reduction must be considered in patients with severe hepatic impairment due to potential for prolonged action.
Pregnancy and lactation eligibility status	Contraindicated in cases of Eclampsia or Pre-eclampsia. Use is not recommended during general pregnancy or while breastfeeding.

These official statements define who is eligible to use the medicine by establishing absolute prohibitions based on cardiovascular and neurological risk, ensuring the medicine is strictly administered only when the documented risks are deemed manageable.

Ketamin-Actavis, containing Ketamine, has officially documented interaction patterns primarily involving pharmacodynamic effects and physical incompatibilities with other products.

Interaction Scope

| Category | Official Regulatory Statement | | :--- | :--- | | Contraindicated Combinations | Co-administration of Theophylline or Aminophylline may lower the seizure threshold. | | Physical Incompatibility | Barbiturates and Diazepam must not be mixed in the same syringe or infusion fluid with Ketamine due to precipitate formation. | | CNS Depressants | Concomitant use with Opioid Analgesics, Benzodiazepines, or other CNS Depressants, including Alcohol, is associated with the risk of profound sedation and respiratory depression. | | Cardiovascular Agents | Sympathomimetics, Vasopressin, and Thyroid Hormones may enhance Ketamine's sympathomimetic effects, which increases the risk of elevated blood pressure and heart rate. | | Anesthetic Agents | Co-administration with Opioid Analgesics or Halogenated Anaesthetics may prolong the time to complete recovery from anesthesia. |

Interaction-Context Constraints

Interactions involving clearance are noted in specific populations: patients with cirrhosis or other liver impairment may experience a prolonged duration of action of Ketamine. This interaction structure is defined by prohibitions, timing rules for injectables, and warnings against additive pharmacodynamic effects documented in regulatory labeling.

The core mechanism involves the drug acting as a non-competitive blocker of the N-methyl-D-aspartate (NMDA) receptor, an excitatory ion channel in the central nervous system. This physical obstruction interrupts glutamate signaling, functionally separating the brain's associative and sensory systems. This action results in a dissociative state and intense central nociceptive signal interruption.

Beyond the primary target, the drug modulates the sympathetic nervous system by inhibiting the reuptake of neurotransmitters like norepinephrine. This effect is correlated with the maintenance of cardiovascular function and the preservation of protective reflexes. Concurrently, auxiliary actions on mu-opioid and other receptor systems influence the molecular mechanisms of central nociceptive signal propagation.

The racemic preparation contains S-(+) and R-(-) ketamine enantiomers. The S-(+) form has a greater binding affinity for the NMDA receptor, which determines its role as the dominant mechanistic driver of the rapid blockade. The mechanism is primarily CNS-focused and does not inherently disrupt the peripheral neuromuscular junction. This functional constraint results in a lack of complete peripheral skeletal muscle relaxation.

Ketamin-Actavis is an injectable solution used under professional supervision for the induction and maintenance of general anesthesia. The application of this medicine is restricted to a controlled medical environment and must be overseen by a physician experienced in anesthetic use.

Administration and Dosage Principles

The medicine is administered through two primary routes: intravenous (IV) injection or intramuscular (IM) injection for the initial induction phase. Intravenous administration requires the dose to be given slowly over a period of 60 seconds to ensure proper procedural control.

Standard adult induction doses are determined by body weight, with the IV regimen typically ranging from 1.0 to 4.5 mg/kg of ketamine base. The IM route uses a higher range, from 6.5 to 13 mg/kg. Maintenance of anesthesia is achieved either through intermittent supplemental doses (one-half to the full induction dose) or by a continuous IV infusion.

Preparation and Special Considerations

The highest concentration of the injection (100 mg/mL) requires dilution with fluids such as 0.9% Sodium Chloride or 5% Dextrose before it can be used intravenously. Dosing may be adjusted based on specific patient factors; for instance, older adults or individuals with hepatic impairment may require a cautious approach, often starting at the low end of the standard dosage range. For elective procedures, the patient should not receive anything by mouth for at least six hours prior to administration.

Recent Clinical Evidence Overview

Clinical research involving the compound in Ketamin-Actavis primarily focuses on its established applications in anesthesia and pain management. These studies adhere to rigorous standards, including randomized controlled trials (RCTs), to provide data on efficacy and safety across various clinical settings.

---

Anesthetic Use

Studies consistently support the compound's role as a dissociative anesthetic. Research has evaluated its utility in emergency medicine, intensive care units, and in procedural sedation. Key findings from clinical evaluations include:

• Hemodynamic Stability: Trials examined the compound's effect profile, often noting that it maintains cardiovascular function better than some traditional anesthetics, making it suitable for patients at risk of hypotension.
• Pediatric Applications: Research has specifically assessed its use and dosing in pediatric patients undergoing short-duration procedures, confirming its utility in this population.

---

Pain Management

Beyond general anesthesia, significant research has focused on its potential in treating chronic and acute pain resistant to standard therapies. While these applications often involve lower, sub-anesthetic doses, they remain important areas of ongoing clinical investigation.

Area of Evaluation	Research Focus
Chronic Pain	Investigating administration methods (e.g., intravenous infusion) for refractory neuropathic pain and complex regional pain syndrome.
Acute Pain	Examining its role as an adjunct therapy to reduce opioid consumption post-operatively.

Studies evaluating pain management applications primarily assess changes in pain scores (e.g., Visual Analog Scale) and patient-reported relief. Data from these trials contribute to understanding its dose-response relationship outside of the operating room.

Key Studies & References

1. The Role of Ketamine in Sedating Hemodynamically Unstable ICU Patients (Clinical Trial/Study on Cardiovascular Effects)
2. The Impact of Ketamine on Outcomes in Acute Pain Management: An Umbrella Review

Common questions about Ketamin-Actavis (FAQ)

Q: Is Ketamin-Actavis the same as regular ketamine?

Ketamin-Actavis is the specific brand name for an injectable solution. The active pharmaceutical ingredient in this medication is Ketamine Hydrochloride. Therefore, it contains the pharmaceutical compound ketamine under the Actavis brand name, which is supplied for professional use.

Q: How quickly does Ketamin-Actavis start working?

The anesthetic effect is rapid. According to official labeling, if the medicine is given intravenously (IV), surgical anesthesia typically occurs within 30 seconds. If administered intramuscularly (IM), the onset usually takes between 3 to 4 minutes.

Q: How long do the effects of Ketamin-Actavis last?

The duration of the anesthetic effect is relatively short. After an intravenous (IV) dose, the effect usually lasts 5 to 10 minutes. Following an intramuscular (IM) dose, the effects tend to last longer, typically between 12 and 25 minutes.

Q: What is the difference between Ketamin-Actavis and other similar drugs I've heard about?

Ketamine belongs to a specific pharmacological group known as a dissociative anesthetic. Official product information notes that, unlike some other anesthetic medications, Ketamine works by separating the brain's associative and sensory systems. This profile is pharmacologically associated with the maintenance of protective reflexes, such as spontaneous breathing.

Q: Does my diet or weight impact how Ketamin-Actavis works?

Yes, both weight and diet are factors in the administration of the medicine. The body weight of the patient is a primary factor used to determine the standard induction doses. Additionally, patients are advised not to eat or drink anything for at least six hours before an elective procedure.

Q: Is Ketamin-Actavis considered a new or an established treatment?

According to official clinical pharmacology information, Ketamine is considered an an established general anesthetic agent. It has been widely used and studied for anesthetic purposes in various patient populations for several decades.

Q: Can Ketamin-Actavis affect my ability to drive or operate machinery?

Due to the potential for impaired judgment and coordination, official precautions advise that hazardous activities requiring mental alertness, such as driving or operating machinery, be avoided for at least 24 hours post-administration.

Q: How long after stopping Ketamin-Actavis will it be completely out of my system?

The elimination of the drug from the body is based on its half-life, which is the time required for the amount of drug to be reduced by half. The half-life of Ketamine’s second elimination phase is approximately 2.5 hours. The action is terminated by the drug’s redistribution and breakdown by the liver.

Q: Is Ketamin-Actavis used in veterinary medicine?

Yes, the compound Ketamine is also supplied and approved for use in veterinary medicine. It is commonly used as an anesthetic or for chemical restraint in various animal species.

Q: Where can I find the official patient information leaflet for Ketamin-Actavis?

The most authoritative documents are the official regulatory documents, such as the Prescribing Information or the Summary of Product Characteristics (SmPC) and its associated Patient Information Leaflet. These can be found on the websites of regulatory bodies like the FDA (DailyMed) or the European Medicines Agency (EMA).

Q: What is Ketamin-Actavis prescribed for besides its main uses?

The official indication for Ketamin-Actavis is its use as an anesthetic agent. This includes using it alone for certain diagnostic and surgical procedures, for inducing anesthesia before using other agents, or to supplement less potent anesthetics. Official regulatory information describes the approved scope of use within a controlled medical environment.

Q: Can Ketamin-Actavis cause long-term problems?

Regulatory documents indicate that no residual psychological effects are known to result from standard anesthetic application. However, warnings are in place regarding severe, long-term risks, such as urinary tract and kidney dysfunction, which have been primarily observed in cases of chronic, repeated non-medical exposure or abuse.

Q: Are there certain foods or drinks I need to avoid when taking Ketamin-Actavis?

Regulatory guidance specifies pre-procedure conditions for the best and safest use of this medicine. For elective procedures, regulatory guidance suggests that a patient should not receive anything by mouth for at least six hours prior to the medication's administration.

Q: Does Ketamin-Actavis interact with common painkillers or supplements?

Official regulatory sources document specific interactions, including with opioid analgesics (a type of painkiller), which can prolong the time it takes to recover from anesthesia. The label does not universally address common non-opioid painkillers or most general supplements.

Q: Is it possible to become tolerant to the effects of Ketamin-Actavis?

Ketamine is classified as a Schedule III Controlled Substance due to its potential for abuse and dependence, which are recognized constraints in its use. The medical concept of tolerance is associated with these mechanisms of dependence and is a factor requiring careful patient monitoring in clinical settings.

Q: Does Ketamin-Actavis interact with any over-the-counter cold medicines?

Regulatory labels warn against combining Ketamine with drugs that stimulate the sympathetic nervous system, known as sympathomimetics. These types of substances are sometimes found in over-the-counter cold medicines (e.g., decongestants) and may enhance the risk of elevated blood pressure and heart rate when combined with Ketamine.

Q: Does Ketamin-Actavis show up on standard drug tests?

The active substance of the medicine is metabolized into compounds that can be detected in the body. While the drug is generally eliminated quickly, these metabolites may be detectable for a longer period. Official regulatory labeling does not specify which standard drug testing panels detect the drug or its metabolites.

Q: What should I do if I suspect a severe or unexpected reaction to Ketamin-Actavis?

In the controlled medical setting where the medicine is administered, medical staff are trained to manage recognized severe risks, such as serious respiratory events or overdose. In the event of an overdose or life-threatening reaction, official labeling specifies the necessity of immediate mechanical support of respiration and other professional supportive measures by the supervising medical team.

Q: Are there known interactions between Ketamin-Actavis and herbal products?

While regulatory labels primarily focus on pharmaceutical interactions, some regulatory-based sources indicate a potential for interaction with herbal products that affect liver function, such as St. John’s Wort, which may potentially influence the drug's effectiveness.

Q: Can Ketamin-Actavis affect my sleep patterns?

Official product information notes that psychological effects, such as vivid dreams or hallucinations, can occur during the emergence (recovery) phase. These phenomena are generally short-lived, usually lasting only a few hours, though rare recurrences up to 24 hours have been reported postoperatively.

Q: Can Ketamin-Actavis interact with antidepressants?

Official labeling generally warns against combining Ketamine with any Central Nervous System (CNS) depressants, as this could lead to profound sedation and respiratory depression. Interactions with specific classes of antidepressants are not universally detailed in the drug's anesthetic-use labels.

Q: Is there a maximum time a person should be on Ketamin-Actavis?

Ketamine is primarily designed for short diagnostic or surgical procedures. While it can be used for longer procedures via continuous infusion, regulatory warnings regarding serious organ risks are associated with extended use (e.g., beyond three days) or chronic non-medical use.

Storage and Disposal of Ketamine Hydrochloride Injection

Official labeling mandates specific conditions for storing Ketamine Hydrochloride Injection. The medicine should be stored at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), and must be protected from light. It is essential that the product does not freeze.

As a controlled substance, this injection must be stored locked up and kept out of the sight and reach of children to prevent unauthorized access.

Stability rules require that the solution be inspected before use for particulate matter or discoloration. Any diluted solution must be used immediately. Multi-dose vials must be discarded 28 days after initial use.

Disposal must adhere to pharmaceutical waste guidelines. Any unused product must be discarded through approved take-back or disposal programs; the medicine must not be thrown in the trash or flushed down the drain to avoid environmental release.